MedMira Inc. is a leading biotechnology firm dedicated to the research, development, manufacturing, and global distribution of rapid diagnostic solutions and advanced technology platforms. The company's operations span North America, Europe, the Asia Pacific region, and other international territories. Its diverse product portfolio includes Reveal HIV, which identifies HIV-1 and HIV-2 antibodies from whole blood, serum, or plasma, and Reveal TP, a quick syphilis antibody test detecting Treponema pallidum antibodies. MedMira also offers the Multiplo series, providing multiplex tests for combined screening of HIV-1/2, Hepatitis B and C, and syphilis, as well as the Miriad triple product for initial HIV and hepatitis screening. Complementing these diagnostic tools is the Miriad RVF toolkit, designed to facilitate the creation and market entry of new rapid diagnostics. Further offerings comprise Reveal HP, an efficient test for Helicobacter pylori (HP) antibodies; VYRA CoV2, which targets SARS-CoV-2 nucleocapsid antigens; VYRA CoV2Flu, a combination viral nucleocapsid antigen test for SARS-CoV-2, Influenza A, and Influenza B; and REVEALCOVID-19, an antibody test for COVID-19. MedMira distributes its products through a robust network of medical distributors and strategic business partners, reaching a broad spectrum of healthcare clients, including laboratories, hospitals, point-of-care clinics, government entities, aid organizations, and public health agencies. Founded in 1993 and headquartered in Halifax, Canada, MedMira Inc. operates as a subsidiary of MedMira Holding AG.
—
MedMira Inc. is a leading biotechnology firm dedicated to the research, development, manufacturing, and global distribution of rapid diagnostic solutions and advanced technology platforms. The company's operations span North America, Europe, the Asia Pacific region, and other international territories. Its diverse product portfolio includes Reveal HIV, which identifies HIV-1 and HIV-2 antibodies from whole blood, serum, or plasma, and Reveal TP, a quick syphilis antibody test detecting Treponema pallidum antibodies. MedMira also offers the Multiplo series, providing multiplex tests for combined screening of HIV-1/2, Hepatitis B and C, and syphilis, as well as the Miriad triple product for initial HIV and hepatitis screening. Complementing these diagnostic tools is the Miriad RVF toolkit, designed to facilitate the creation and market entry of new rapid diagnostics. Further offerings comprise Reveal HP, an efficient test for Helicobacter pylori (HP) antibodies; VYRA CoV2, which targets SARS-CoV-2 nucleocapsid antigens; VYRA CoV2Flu, a combination viral nucleocapsid antigen test for SARS-CoV-2, Influenza A, and Influenza B; and REVEALCOVID-19, an antibody test for COVID-19. MedMira distributes its products through a robust network of medical distributors and strategic business partners, reaching a broad spectrum of healthcare clients, including laboratories, hospitals, point-of-care clinics, government entities, aid organizations, and public health agencies. Founded in 1993 and headquartered in Halifax, Canada, MedMira Inc. operates as a subsidiary of MedMira Holding AG.
—
Daily adjusted close
MedMira Inc. is a leading biotechnology firm dedicated to the research, development, manufacturing, and global distribution of rapid diagnostic solutions and advanced technology platforms. The company's operations span North America, Europe, the Asia Pacific region, and other international territories. Its diverse product portfolio includes Reveal HIV, which identifies HIV-1 and HIV-2 antibodies from whole blood, serum, or plasma, and Reveal TP, a quick syphilis antibody test detecting Treponema pallidum antibodies. MedMira also offers the Multiplo series, providing multiplex tests for combined screening of HIV-1/2, Hepatitis B and C, and syphilis, as well as the Miriad triple product for initial HIV and hepatitis screening. Complementing these diagnostic tools is the Miriad RVF toolkit, designed to facilitate the creation and market entry of new rapid diagnostics. Further offerings comprise Reveal HP, an efficient test for Helicobacter pylori (HP) antibodies; VYRA CoV2, which targets SARS-CoV-2 nucleocapsid antigens; VYRA CoV2Flu, a combination viral nucleocapsid antigen test for SARS-CoV-2, Influenza A, and Influenza B; and REVEALCOVID-19, an antibody test for COVID-19. MedMira distributes its products through a robust network of medical distributors and strategic business partners, reaching a broad spectrum of healthcare clients, including laboratories, hospitals, point-of-care clinics, government entities, aid organizations, and public health agencies. Founded in 1993 and headquartered in Halifax, Canada, MedMira Inc. operates as a subsidiary of MedMira Holding AG.